Barclays Downgrades Oncobiologics (ONS) to Equalweight Citing Lack of Business Clarity
Tweet Send to a Friend
Barclays downgraded Oncobiologics (NASDAQ: ONS) from Overweight to Equalweight ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
